Elutia, Inc. · NASDAQ:ELUT
Elutia — LD Micro Main Event XIX Conference (October 2025)
19 slides from Elutia's conference presentation, Oct 21, 2025
Slide 1: LD Micro Main Event XIX Conference
LD Micro Main Event XIX Conference C. Randal Mills PhD Chief Executive Officer Matt Ferguson Chief Financial Officer October 21st, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation of Elutia Inc. (“Elutia,” “we,” “us,” “our” or the “Company”) (together with any other statements or information that we may make or discuss in connection herewith) contains forward-looking statements. All statements other than statements of historical fa
Slide 3: Our Mission
Our Mission so patients can thrive without compromise. 3
Slide 4: What is our strategy?
is our What strategy? Replace stagnant, commodity biologic materials with a new class of drug-enhanced biomaterials that deliver superior outcomes and clear clinical differentiation, starting in breast reconstruction. And we are doing it better and faster than anyone else. 4
Slide 5: What are we great at?
are we What great at? Optimal Biologic Matrix + Powerful Antibiotics Sustained antibiotic release to prevent infection and associated complications. Sold to Boston Scientific for $88M 5
Slide 6: Investment Highlights
Investment Highlights Validated Technology Blockbuster Fully Platform Pipeline Resourced Proven team and state-of- Developed first FDA-cleared Taking the same technology the-art GMP facility and drug-eluting bioenvelope for platform into the the $1.5B commercial platform pacemakers breast reconstruc
Slide 7: She's too important
This year,316,950 women will be diagnosed with invasive breast cancer. She’s 1 in 3 will suffer too important serious complications from reconstruction. We aim to change that. 7
Slide 8: Why breast reconstruction is a transformational opportunity
breast is a transformational Why reconstruction opportunity Very Large Market Breast reconstruction is a $1.5B market. 8
Slide 9: Why breast reconstruction: very real unmet need
breast is a transformational Why reconstruction opportunity Very Real Large Unmet One in three Market Need patients face serious Breast reconstruction complications - is a $1.5B market. 1 in 7 face infection 9
Slide 10: Why breast reconstruction: solved by our platform
breast is a transformational Why reconstruction opportunity First FDA-cleared Solved by Drug-Eluting Our Platform Now addressing breast reconstruction. BioEnvelope Very Real Unmet One in three Large patients face serious Market Need Breast reconstruction complications - is a $1.5B market. 1 in 7 fac
Slide 11: 317,000 Women Will be Diagnosed with Invasive Breast Cancer in the US in 2025
317,000 Women Will be Diagnosed with Invasive Breast Cancer in the US in 2025 Of the women who require a mastectomy only 40% opt for reconstruction. Mastectomy Mastectomy + Only Understanding Reconstruction 60% Mastectomy 40% 11
Slide 12: Breast Reconstruction is a Big Market
Breast Reconstruction is a Big Market Biologics represent a $1.5B US TAM and 65% of reconstruction spend $11,538 spent per breast • There are ≈ 160,000 breasts reconstructed after mastectomy annually Implant Biologic • Biologic mesh is used in >90% of Matrix reconstruction cases 15% ($7,500) • hADMs
Slide 13: Despite the high cost, the status quo isn't addressing the problem
Despite the high cost, the status quo isn’t addressing the problem patients suffer serious complications 1 in 3 after reconstruction $48,344 1 in 7 experience infection average economic cost to the hospital of breast reconstruction up to 21% result in implant loss infection Reish RG et al. Plast Rec
Slide 14: Proof of Concept: Local antibiotic delivery works in breast reconstruction
Proof of Concept: Local antibiotic delivery works in breast reconstruction PMMA plate with antibiotics Antibiotic discs & antibiotic beads • Plates permanent, not resorbable • Made from resorbable cement • Can get dislodged, stretches skin • Historically used in orthopedic surgery • Pressure of plat
Slide 15: That's why we created NXT-41x
That’s why we created what’s NXT NXT-41x Optimal Biologic Matrix Engineered extracellular matrix Purpose-built for biological remodeling + Powerful Antibiotics Rifampin and Minocycline Sustained release with > 30 days above MIC 15
Slide 16: Rifampin + Minocycline: Killing the Pathogens that Matter
Rifampin + Minocycline: Killing the Pathogens that Matter Kills Common Pathogens in Breast Reconstruction: ✓ Staphylococcus aureus (including MRSA) – Primary cause of implant infection; highly virulent. ✓ Staphylococcus epidermidis – skin flora forming biofilms on implants. ✓ Pseudomonas aeruginosa,
Slide 17: We are leveraging our proven development experience to efficiently gain market authorization
We are leveraging our proven development experience to efficiently gain market authorization Same regulatory pathway used for EluPro: ✓ NXT-41 Matrix Developed - COMPLETE ✓ NXT-41 Animal Data - COMPLETE ✓ NXT-41x FDA Pre-sub Meeting - COMPLETE • NXT-41 Matrix FDA Filing 1H26 • NXT-41 Matrix FDA Clea
Slide 18: Investment Summary
Investment Summary Why Own Elutia Now? Here are three good reasons. We have a: ✓ Validated technology platform that physicians adopt and strategics value ✓ De-risked path to first-in-class $1.5B market with a significant unmet need ✓ Team and capital to get there without dilution 18
Slide 19: Thank you
Thank you *) ELUTIA Medicine Humanized”
Elutia — LD Micro Main Event XIX Conference (October 2025) on 6ix